These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10514498)

  • 1. von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells.
    Kroll SL; Paulding WR; Schnell PO; Barton MC; Conaway JW; Conaway RC; Czyzyk-Krzeska MF
    J Biol Chem; 1999 Oct; 274(42):30109-14. PubMed ID: 10514498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous von Hippel-Lindau tumor suppressor protein regulates catecholaminergic phenotype in PC12 cells.
    Bauer AL; Paulding WR; Striet JB; Schnell PO; Czyzyk-Krzeska MF
    Cancer Res; 2002 Mar; 62(6):1682-7. PubMed ID: 11912140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors.
    Schnell PO; Ignacak ML; Bauer AL; Striet JB; Paulding WR; Czyzyk-Krzeska MF
    J Neurochem; 2003 Apr; 85(2):483-91. PubMed ID: 12675925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.
    Lonergan KM; Iliopoulos O; Ohh M; Kamura T; Conaway RC; Conaway JW; Kaelin WG
    Mol Cell Biol; 1998 Feb; 18(2):732-41. PubMed ID: 9447969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.
    Pioli PA; Rigby WF
    J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
    Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG
    Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
    Ohh M; Takagi Y; Aso T; Stebbins CE; Pavletich NP; Zbar B; Conaway RC; Conaway JW; Kaelin WG
    J Clin Invest; 1999 Dec; 104(11):1583-91. PubMed ID: 10587522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
    Tsuchiya H; Iseda T; Hino O
    Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The von Hippel-Lindau tumour suppressor protein: new perspectives.
    Ohh M; Kaelin WG
    Mol Med Today; 1999 Jun; 5(6):257-63. PubMed ID: 10366821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of transcription elongation by the VHL tumor suppressor protein.
    Duan DR; Pause A; Burgess WH; Aso T; Chen DY; Garrett KP; Conaway RC; Conaway JW; Linehan WM; Klausner RD
    Science; 1995 Sep; 269(5229):1402-6. PubMed ID: 7660122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
    Ivanova AV; Ivanov SV; Danilkovitch-Miagkova A; Lerman MI
    J Biol Chem; 2001 May; 276(18):15306-15. PubMed ID: 11278694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein.
    Pause A; Peterson B; Schaffar G; Stearman R; Klausner RD
    Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9533-8. PubMed ID: 10449727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
    Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter.
    Rafty LA; Khachigian LM
    J Cell Biochem; 2002; 85(3):490-5. PubMed ID: 11967988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.
    Takagi Y; Pause A; Conaway RC; Conaway JW
    J Biol Chem; 1997 Oct; 272(43):27444-9. PubMed ID: 9341197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues.
    Corless CL; Kibel AS; Iliopoulos O; Kaelin WG
    Hum Pathol; 1997 Apr; 28(4):459-64. PubMed ID: 9104946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
    J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.